Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Dustin Portela, DO, is a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho.

In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.

Pointers With Portela: Minimalist Skin Care Routines

Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.

New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

View

News 

Pilot study shows nine patients with pruritus respond well to topicalmast cell stabilizerNew Orleans - Results of a pilot study suggest the mast cell stabilizercromolyn may be an innovative new topical therapy for itch, Larry E. Millikan,M.D., said.

Cromolyn shows potential for topical itch relief